Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.56 |
| ▸ | MEN1 | O00255 | 4/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30958764 | 1.00 | TSHR (0.57) | TSHRKMT2AMEN1L3MBTL1ATM | |
| SCHEMBL651847 | 0.89 | KMT2A (0.58) | TSHRKMT2AMEN1L3MBTL1LMNA | |
| SCHEMBL29638283 | 0.89 | KMT2A (0.58) | TSHRKMT2AMEN1L3MBTL1LMNA | |
| SCHEMBL30866830 | 0.84 | TSHR (0.59) | TSHRKMT2AMEN1L3MBTL1ATM | |
| SCHEMBL5261945 | 0.84 | TSHR (0.59) | TSHRKMT2AMEN1L3MBTL1ATM | |
| SCHEMBL13311778 | 0.82 | KMT2A (0.60) | TSHRKMT2AMEN1L3MBTL1ATM | |
| SCHEMBL692761 | 0.82 | L3MBTL1 (0.60) | TSHRKMT2AMEN1L3MBTL1ATM | |
| SCHEMBL29595267 | 0.82 | L3MBTL1 (0.60) | TSHRKMT2AMEN1L3MBTL1ATM | |
| SCHEMBL12418312 | 0.82 | KMT2A (0.60) | TSHRKMT2AMEN1L3MBTL1ATM | |
| SCHEMBL27359666 | 0.82 | KMT2A (0.60) | TSHRKMT2AMEN1L3MBTL1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108503584-B | 1,2,3, 4-tetrahydroquinoline sulfonamide compound and application thereof | 复旦大学 | 2021-05-04 | — | — | CN | claimed |
| CN-108503584-A | A kind of 1,2,3,4- tetrahydroquinolines sulfamide compound and its application | 复旦大学 | 2018-09-07 | — | — | CN | claimed |
| US-7964603-B2 | Substituted tetrahydro-quinoline-sulfonamide compounds, their preparation and use as medicaments | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-06-21 | — | — | US | claimed |
| EP-2016943-B1 | Substituted tetrahydro-quinoline-sulfonamide compounds, their preparation and use as medicaments | ESTEVE LABOR DR (ES) | 2011-02-23 | — | — | EP | claimed |
| US-20090030013-A1 | SUBSTITUTED TETRAHYDRO-QUINOLINE-SULFONAMIDE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIES DEL DR. ESTEVE, S.A. (ES) | 2009-01-29 | — | — | US | claimed |
| EP-2016943-A1 | Substituted tetrahydro-quinoline-sulfonamide compounds, their preparation and use as medicaments | Laboratorios del Dr. Esteve S.A. (ES) | 2009-01-21 | — | — | EP | claimed |
| US-12187742-B2 | Dual ATM and DNA-PK inhibitors for use in anti-tumor therapy | XRAD THERAPEUTICS, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| US-20240228463-A1 | SODIUM CHANNEL INHIBITORS AND METHODS OF DESIGNING SAME | GENENTECH, INC. (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240228463-A1 | SODIUM CHANNEL INHIBITORS AND METHODS OF DESIGNING SAME | GENENTECH, INC. (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240228463-A1 | SODIUM CHANNEL INHIBITORS AND METHODS OF DESIGNING SAME | GENENTECH, INC. (US) | 2024-07-11 | — | — | US | disclosed |
| WO-2023028077-A1 | SODIUM CHANNEL INHIBITORS AND METHODS OF DESIGNING SAME | GENENTECH, INC. (US) | 2023-03-02 | — | — | WO | disclosed |
| US-20220315606-A1 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | XRAD HOLDING CAYMAN LIMITED (KY) | 2022-10-06 | — | — | US | disclosed |
| CN-108503584-B | 1,2,3, 4-tetrahydroquinoline sulfonamide compound and application thereof | 复旦大学 | 2021-05-04 | — | — | CN | disclosed |
| EP-2016943-B1 | Substituted tetrahydro-quinoline-sulfonamide compounds, their preparation and use as medicaments | ESTEVE LABOR DR (ES) | 2011-02-23 | — | — | EP | disclosed |
| EP-2016943-B1 | Substituted tetrahydro-quinoline-sulfonamide compounds, their preparation and use as medicaments | ESTEVE LABOR DR (ES) | 2011-02-23 | — | — | EP | disclosed |
| US-20090030013-A1 | SUBSTITUTED TETRAHYDRO-QUINOLINE-SULFONAMIDE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIES DEL DR. ESTEVE, S.A. (ES) | 2009-01-29 | — | — | US | disclosed |
| US-20090030013-A1 | SUBSTITUTED TETRAHYDRO-QUINOLINE-SULFONAMIDE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIES DEL DR. ESTEVE, S.A. (ES) | 2009-01-29 | — | — | US | disclosed |
| EP-2016943-A1 | Substituted tetrahydro-quinoline-sulfonamide compounds, their preparation and use as medicaments | Laboratorios del Dr. Esteve S.A. (ES) | 2009-01-21 | — | — | EP | disclosed |
| EP-2016943-A1 | Substituted tetrahydro-quinoline-sulfonamide compounds, their preparation and use as medicaments | Laboratorios del Dr. Esteve S.A. (ES) | 2009-01-21 | — | — | EP | disclosed |
| EP-2016943-A1 | Substituted tetrahydro-quinoline-sulfonamide compounds, their preparation and use as medicaments | Laboratorios del Dr. Esteve S.A. (ES) | 2009-01-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228463-A1 | SODIUM CHANNEL INHIBITORS AND METHODS OF DESIGNING SAME | CACNA1I, CACNA1B, CACNA1C | TSHR 3592/4885KMT2A 2619/4885MEN1 1307/4885 |
| US-20220315606-A1 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | ATM, CHEK2, CHEK1 | TSHR 2841/4885KMT2A 918/4885MEN1 2696/4885 |
| US-12187742-B2 | Dual ATM and DNA-PK inhibitors for use in anti-tumor therapy | ATM, CHEK2, CHEK1 | TSHR 2841/4885KMT2A 918/4885MEN1 2696/4885 |
| US-20090030013-A1 | SUBSTITUTED TETRAHYDRO-QUINOLINE-SULFONAMIDE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS | HTR6, HTR5A, HTR7 | TSHR 498/4885KMT2A 1918/4885MEN1 2064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.